Stocks Health care VYGR
NASDAQ · Health careVoyager Therapeutics, Inc. (VYGR)
Voyager Therapeutics, Inc. brought in $25.1M of revenue over the twelve months to September 30, 2026, down 19.8% from a year earlier. It posted a net loss of $104.5M. In fiscal 2025 capital spending exceeded operating cash flow by $135.1M. At September 30, 2026 it held $48.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Voyager Therapeutics, Inc.
- Net worth
- Voyager Therapeutics, Inc. has a market value (market cap) of $112.5M at the latest share price, and shareholders' equity of $135.1M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $40.4M (-49.5% year on year), with a net loss of $119.7M. Over the 12 months to September 30, 2026: revenue $25.1M, net loss $104.5M.
- Cash flow
- In fiscal 2025 operations used $132.5M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Voyager Therapeutics, Inc.'s next report was expected around November 9, 2026 and is not on file with the SEC yet.
What Voyager Therapeutics, Inc. does
Voyager Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker VYGR.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $40.4M | -$119.7M | -$2.04 | -$135.1M |
| 2024 | $80M | -$65M | -$1.13 | -$18.8M |
| 2023 | $250M | $132.3M | $2.97 | $74.7M |
| 2022 | $40.9M | -$46.4M | -$1.21 | -$15M |
| 2021 | $37.4M | -$71.2M | -$1.89 | -$55.1M |
| 2020 | $171.1M | $36.7M | $0.98 | -$108.8M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where VYGR ranks in Health care
Latest SEC filings
What Voyager Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026
- November 5, 2026Quarterly report 10-Q · period to September 30, 2026Revenue fell 70% to $4M versus the same quarter last year; diluted EPS -$0.40 versus -$0.47.
- October 21, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 6, 2026
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 39% to $3.2M versus the same quarter last year; diluted EPS -$0.40 versus -$0.57.
- July 31, 2026Passive stake changed SCHEDULE 13G/A
- July 13, 2026Other event 8-K
- June 10, 2026
- June 1, 2026Other event 8-K
Insider trades
What the people running Voyager Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 2 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 1, 2026 | Swartz RobinPresident | Received as pay | 68,250 | - |
| November 1, 2026 | Carter Todd AlfredChief Scientific Officer | Received as pay | 33,000 | - |
| April 2, 2026 | Sandrock AlfredPresident and CEO, Director | Soldpre-planned (10b5-1) | 11,511 | $44.5K |
| April 1, 2026 | Shiferman Gregory L.SVP and General Counsel | Received as pay | 50,000 | - |
| February 24, 2026 | Carter Todd AlfredChief Scientific Officer | Soldpre-planned (10b5-1) | 4,174 | $15.7K |
| February 24, 2026 | Jorgensen Nathan D.Chief Financial Officer | Soldpre-planned (10b5-1) | 4,668 | $17.6K |
| February 24, 2026 | Sandrock AlfredPresident and CEO, Director | Soldpre-planned (10b5-1) | 14,197 | $53.8K |
| February 24, 2026 | Swartz RobinCOO & CBO | Soldpre-planned (10b5-1) | 6,458 | $24.3K |
Who owns VYGR
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Millennium Management LLC13G, passive with 3 related filers | 7.4% | July 31, 2026 |
| Armistice Capital, LLC13G, passive with 1 related filers | 5.58% | August 14, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 136 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 5,172,063 | -396,318 |
| Millennium Management LLC | 4,442,951 | +1,014,380 |
| Armistice Capital, LLC | 3,436,000 | -64,000 |
| Vestal Point Capital, LP | 2,625,000 | -377,936 |
| Vanguard Capital Management LLC | 2,345,674 | +62,421 |
| Geode Capital Management, LLC | 1,330,492 | +280,514 |
| Opaleye Management Inc. | 1,185,000 | +35,000 |
| State Street Corp | 1,076,422 | +128,196 |
| Two Sigma Investments, LP | 948,517 | +332,857 |
| Dimensional Fund Advisors LP | 838,184 | -37,384 |
| Vanguard Portfolio Management LLC | 810,091 | +84,322 |
| Citadel Advisors LLC | 784,067 | +419,403 |
| Morgan Stanley | 697,334 | +15,623 |
| Erste Asset Management GmbH | 638,900 | -456,241 |
| Renaissance Technologies LLC | 495,236 | -82,788 |
| Sphera Funds Management Ltd. | 427,554 | -42,207 |
| Diadema Partners LP | 413,642 | -10,000 |
| Northern Trust Corp | 411,803 | +26,960 |
| Aqr Capital Management LLC | 356,109 | +123,428 |
| Goldman Sachs Group Inc | 338,477 | -89,120 |
Insiders
6 insiders reported holding 1,304,585 shares in total, about $2.4M at the last price.
| Holder | Shares |
|---|---|
| Sandrock AlfredPresident and CEO, Director | 472,549 |
| Swartz RobinPresident | 267,988 |
| Ferguson TobyChief Medical Officer | 183,914 |
| Carter Todd AlfredChief Scientific Officer | 178,718 |
| Jorgensen Nathan D.Chief Financial Officer | 151,416 |
| Shiferman Gregory L.SVP and General Counsel | 50,000 |
Questions about VYGR
What does Voyager Therapeutics, Inc. do?
Voyager Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as VYGR. Its shares trade on NASDAQ under the ticker VYGR.
What is Voyager Therapeutics, Inc.'s net worth?
Voyager Therapeutics, Inc. has a market value (market cap) of $112.5M at the latest share price, and shareholders' equity of $135.1M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Voyager Therapeutics, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $104.5M on revenue of $25.1M.
How much revenue does Voyager Therapeutics, Inc. make?
Over the twelve months to September 30, 2026 Voyager Therapeutics, Inc. reported revenue of $25.1M. That is 19.8% less than a year earlier.
When did Voyager Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026.
When is Voyager Therapeutics, Inc.'s next earnings report?
Voyager Therapeutics, Inc.'s next report was expected around November 9, 2026 and is not on file with the SEC yet.
Similar companies
Compare VYGR with
Follow VYGR
Get an email when Voyager Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Voyager Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.